CliffBio
small molecule

INREBIC

FEDRATINIB HYDROCHLORIDE

Loss of exclusivitySeptember 2039latest FDA-listed patent expiry
CompanyBristol Myers Squibb →See this company's full patent-cliff portfolio

Drug detail

Brand nameINREBIC
Active ingredientFEDRATINIB HYDROCHLORIDE
StrengthEQ 100MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2019
Marketing statusRX

Listed patents

PatentExpiresType
11400092September 2039use U-3409
10391094June 2032product
7528143November 2031substance, product
8138199June 2028use U-2607
7825246December 2026substance

Regulatory exclusivity

CodeExpires
ODE-259August 2026

More from Bristol Myers Squibb

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.